ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$18.75 USD
-0.39 (-2.04%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $18.76 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Price, Consensus and EPS Surprise
ACAD 18.75 -0.39(-2.04%)
Will ACAD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACAD
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
Other News for ACAD
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
Clinical Data from Open-Label Extension LILAC-1? and LILAC-2? Studies Evaluating Long-Term Safety and Efficacy of DAYBUE? (trofinetide) in Patients with Rett Syndrome Published in Med
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Acadia Pharmaceuticals initiated with bullish view at BMO Capital, here's why
ACADIA Pharmaceuticals (ACAD) Gets a Buy from RBC Capital